Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 245

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 245
---
 –91.46% |
| Expected term (in years)                           |     |       4.99 – 5.59 |
| Expected dividend yield                            |     |                0% |

The Company determines the assumptions used in the option pricing model in the following manner: Risk-Free Interest Rate—For the determination of the risk-free interest rates, the Company utilizes the U.S. Treasury yield curve for instruments in effect at the time of measurement with a term commensurate with the expected term assumption. Expected Volatility—Due to the Company’s limited historical stock price volatility data, the Company based its estimate of expected volatility on the estimated and expected volatilities of a guideline group of publicly traded companies. For these analyses, the Company selected companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the - 173 -

expected life of the share-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of its share-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. Expected Dividend—The expected dividend yield is assumed to be zero because the Company has never paid dividends and does not have current plans to pay any dividends on its common stock. Expected Term—The Company estimates the expected term of its stock options granted to employees and non-employeedirectors using the simplified method, whereby, the expected term equals the average of the vesting term and the original.

| (2) | As of December 31, 2024, Dr. Castelein held options to purchase 117,727 shares of Company common 
 stock.                                                                                           |

| (3) | As of December 31, 2024, Dr. Dalal held options to purchase 117,727 shares of Company common stock 
 and 486 shares of common stock, respectively.                                                      |

| (4) | As of December 31, 2024, Ms. Reeve held options to purchase 109,146 shares of Company common stock. |

| (5) | As of December 31, 2024, Dr. Aghazadeh held options to purchase 110,209 shares of Company common 
 stock.                                                                                           |

| (6) | As of December 31, 2024, Dr. Hehenberger held options to purchase 110,209 shares of Company common